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mmHg increase: 1.0676, p< .001) as a significant risk factor for stroke in addition to 
age and diabetes, among others. ConClusions: This stroke risk equation shows 
that greater PP is a significant predictive factor for increased stroke risk, even in the 
presence of known risk factors, including SBP. PP should be considered by practi-
tioners along with traditional risk factors in treatment strategies to prevent stroke.
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objeCtivos: Las enfermedades cardiovasculares (ECV) son una de las principales 
causas de muerte precoz en los países occidentales, los fármacos hipolipemiantes 
están indicados para disminuir el riesgo cardiovascular V. El objetivo de este análisis 
es evaluar la costo-efectividad del uso de estatinas en prevención primaria de ECV en 
Colombia. MetodologíAs: Se utilizó un modelo compuesto por un árbol de decisión y 
un Markov. El horizonte de tiempo fue la expectativa de vida. Los comparadores fueron: 
atorvastatina (20mg/día) vs. rosuvastatina (20 mg/día). Se simuló una cohorte de 100 
pacientes de 62 años con valor inicial de colesterol LDL de 137.28mg/dL y riesgo anual 
basal de ECV ≤ 3.5%. Se utilizó una tasa de descuento de 3%. Los datos de utilidad, eficacia 
y mortalidad por los eventos fueron tomados de la literatura, ajustados por información 
local. La medida de efectividad empleada fueron los años de vida ganados (AVG), los 
años de vida ajustados por calidad (AVACs) y los casos de ECV evitados. Los precios de 
los medicamentos fueron tomados del SISMED y los costos de una EPS de presencia 
nacional. Se utilizó como umbral de disposición a pagar, el equivalente a 3 PIB per cápita 
≈ US$40,000. ResultAdos: En el horizonte de la expectativa de vida, el ahorro total 
esperado por persona con atorvastatina fue de US$6374 en comparación con rosuvas-
tatina (costos totales: US$8,802 y US$15,176, respectivamente); rosuvastatina obtuvo 
0.0108 AVACs, 0.0127 AVG y 0.0023 casos evitados más que atorvastatina por persona; el 
ICER de rosuvastatina fue de US$507,266/AVAC, US$426,320/AVG y US$2,624,876/casos 
evitados de ECV. ConClusiones: Atorvastatina sería la alternativa de elección en la 
prevención de ECV. El diferencial de AVG, AVACs y casos de ECV de rosuvastatina es muy 
bajo para su costo incremental y su ICER se encuentra por encima del umbral definido, 
por lo que no es una opción costo-efectiva.
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objeCtives: Estimate potential direct savings for the Mexican Healthcare System 
generated by the operation of the “Technical Guidelines for the Sale or Distribution 
of Food and Beverages in Establishments of Basic Education”. Methods: The micro-
simulation model “Chronic Disease Prevention (CDP)” developed by OECD-WHO was 
used for projecting health gains and costs of treatment in a period of 100 years. The 
model was adjusted to accommodate the range 6-14 years old stated in the Guidelines. 
Mexican data on incidence, prevalence, mortality, population at risk, annual unit costs 
and relative risk of selected chronic diseases (diabetes mellitus type 2, hypertension, car-
diovascular, hypercholesterolemia) attributable to obesity and the treatment of obesity 
as disease itself was used. Sensitivity analyses were developed for most variables used 
in the model. Results: Under a base case scenario present value of potential savings 
in total spending on medical care associated with the implementation of the Guidelines 
amount to USD$1052.2 million in 2008. Most savings are derived from averted cases of 
hypertension (32.7%), obesity-overweight (28.6%) and diabetes mellitus type II (17.8%). 
Results are robust to changes in all parameters analyzed. Amounts obtained are an 
underestimation of potential savings as neither expensive complications as renal failure 
nor other chronic diseases attributable to obesity as arthritis, colorectal or breast cancer 
were included. ConClusions: The Guidelines, —developed by the Ministry of Public 
Education in coordination with the Ministry of Health—, represent a good example of 
cooperation among different sectors to solve a complex public health problem. Results 
shows the importance of implementing preventive interventions aimed at reducing 
the prevalence of chronic diseases related to poor eating habits, inadequate physical 
activity and obesity in Mexico. Implementation of the Guidelines involves significant 
direct savings that can be assigned to other health needs of the Mexican population.
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objeCtives: To explore the effect of health spending, income inequality and 
margination on maternal and child health care in México. Methods: With the 
32 Mexican states an ecological multi spatial study was performed. Correlations 
between maternal and infant mortalities in the total per capita spending (cen-
tral and state governments from 2000 to 2010), Gini and margination indexes 
were computed. Conventional and robust multiple linear regressions were used 
to explore the effects on the technical efficiency of these indicators in the 
State’s health systems. Results: Negative correlations with Spearman rho -0.62 
and -0.28 near to the margination and Gini indexes respectively (p < 0.05), and 
higher than 0.59 for the margination index (p < 0.05) between life expectancy at 
birth for the first and the last infant mortality. The multiple linear regression 
models established the relationship between the deprivation and Gini indexes 
in health indicators. It showed the positive effect of funding from central gov-
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objeCtivos: El síndrome coronario agudo (SCA) representa alta carga de la enfermedad 
para México. Los biomarcadores cardiacos Point of Care Testing (POCT) mejoran la oportu-
nidad diagnóstica, permiten acelerar el tratamiento y reducen la mortalidad. El propósito 
del estudio fue evaluar, desde la perspectiva del proveedor de servicios de salud, su 
impacto clínico y económico en los servicios de urgencias en México. MetodologíAs: 
Estudio comparativo, en situaciones habituales, del servicio de urgencias del Hospital 
General de Zona No. 1-A del Instituto Mexicano del Seguro Social (IMSS) en México, 
D.F. Los grupos de comparación fueron: sin disponibilidad de biomarcadores POCT, que 
incluyó pacientes adultos, sin distinción de género, que acudieron al hospital por dolor 
torácico agudo (DTA) entre marzo y abril de 2012; y con disponibilidad de biomarcadores 
POCT, que incluyó pacientes que acudieron entre junio y septiembre de 2012. Se realizó 
seguimiento durante la estancia en urgencias. El resultado de interés fue la identificación 
de pacientes con SCA. Los costos se calcularon con los recursos utilizados durante la 
estancia en urgencias; se expresaron de dólares norteamericanos (tasa de cambio 12.65 
pesos/dólar). ResultAdos: Se incluyeron 336 pacientes, edad promedio 55±18 años, 
52% hombres. El grupo sin POCT incluyó 148 pacientes y con POCT 188. Con POCT se 
identificaron 50 pacientes con SCA (0.27, IC95% 0.20–0.33) vs 21 sin POCT (0.14, IC95% 
0.08–0.19), p= 0.006. El costo promedio de la atención en urgencias con POCT fue US$178 
(IC95% US$161-US$ 340) y sin POCT fue de US$168 (IC95% US$152-US$320), p= 0.93. El 
costo-efectividad promedio para identificar un paciente con SCA sin POCT fue US$1,206 
y con POCT fue US$661. ConClusiones: La disponibilidad de biomarcadores POCT 
en urgencias es costo-efectivo, ya que mejora la probabilidad de identificar SCA en 
pacientes con DTA y no existe diferencia en el costo de su implementación para el IMSS.
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objeCtives: Atrial Fibrillation (AF) affects about 2% of the population and increases 
5-fold the risk of stroke and systemic embolism. This risk is managed with vitamin K 
antagonists (VKA) or aspirin for patients according to their suitability to receive oral 
anticoagulants (OA) but with several limitations. Therefore, novel OAs have become 
a treatment option. Apixaban is the most recent drug approved for thrombotic pre-
vention in AF. Our aim is to estimate the cost-effectiveness (CE) of apixaban in AF in 
Argentina. Methods: We conducted a literature review of published epidemiologi-
cal AF, and stroke data from Argentina. Data about apixaban, warfarin, rivaroxaban, 
dabigatran and aspirin were obtained from published trials and indirect comparisons. 
Two Delphi Panels, with local experts representing private, public and social security 
health subsectors were held and reviewed and validated data collected and provided 
information on local treatment patterns. Costs, expressed in 2012U$S, were gathered 
from published reports and a local database. Apixaban was compared with each avail-
able AF treatment option allocating them into a simulated cohort of 1,000 patients 
per treatment group (according with their suitability for OA) over a lifetime horizon 
using an MS EXCEL based Markov model. We adopted payer’s perspective reporting 
weighted mean costs for QALY gained. CE threshold for Argentina was considered as 
per WHO-CHOICE and World Bank data (ranging from 9740 to 29220U$S). Results: 
For the suitable population, the cost per QALY gained with apixaban was U$S 9938 and 
1131 versus warfarin and dabigatran 150 mg respectively, and dominant compared 
to dabigatran 110 mg and rivaroxaban. For the unsuitable population, apixaban was 
dominant compared to available alternatives: aspirin, dabigatran 110 mg, dabigatran 
150 mg, and rivaroxaban. ConClusions: on the model using local inputs, apixaban 
is dominant or cost-effective according to local CE thresholds becoming the treatment 
choice in Argentina both in the suitable and unsuitable populations
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objeCtives: Previous stroke risk equations identified systolic blood pressure (SBP) 
as a key predictive factor. Recent evidence suggests that pulse pressure (PP), defined 
as the difference between SBP and diastolic blood pressure, could be a new risk 
factor. This project aims at developing and validating a new stroke risk equation 
incorporating PP as a potential risk factor. Methods: Electronic medical records 
including laboratory data of a random sample of 97,237 hypertensive patients from 
a US integrated health delivery system were analyzed (01/2004-05/2012). Patients 
with ≥ 1 peripheral PP (PPP) reading and ≥ 6 months of observation (baseline period) 
prior to the first evidence of hypertension were randomly split into the development 
(two-thirds of sample) and validation (one-third of sample) datasets. Stroke events 
were identified using ICD-9-CM 433.xx-436.xx. Cox proportional hazards models 
assessed time to first stroke event based on baseline risk factors, including PPP, age, 
gender, SBP, smoking status, BMI, diabetes, and cardiac comorbidities. The optimal 
risk equation was selected using the least absolute shrinkage and selection operator 
(LASSO); performance was evaluated by the c-statistic. Results: A total of 30,525 
patients without stroke (mean age 58.2, 48% male) and 4,272 patients with stroke 
(mean age 67.3, 48% male) were selected. Average observation was 3.89 years. PPP 
was higher among patients who developed stroke (mean [SD] PPP, stroke: 62.0 [15.3] 
mmHg; non-stroke: 58.1 [14.0] mmHg, p< .001). The best performing risk equation 
(c-statistic, development: 0.732; validation: 0.722) included PPP (hazard ratio per 10 
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ate the efficacy and safety of new anticoagulants in the treatment of AF. Methods: 
Health Technology Assessment of multiple technologies. We searched the electronic 
databases Cochrane Library, CRD, Pubmed, Embase and Lilacs, to search for the best 
available evidence assessing the new oral anticoagulants, compared with warfa-
rin in patients with AF. Results: Three randomized controlled trials evaluating 
dabigatran (110mg e 150mg), rivaroxaban 20mg and apixaban 5mg were included, 
all of them compared with warfarin. In this regard, dabigatran 110mg was associ-
ated with similar rates of stroke or systemic embolism and with a 20% relative risk 
reduction (RRR) of major hemorrhage compared with warfarin. Dabigatran 150mg 
was associated with a 34% RRR of stroke or systemic embolism and similar rates 
of major hemorrhage. Rivaroxaban 20mg was associated with similar rates of the 
primary efficacy and safety outcomes. Finally, apixaban was associated with a 21% 
RRR of stroke or systemic embolism and with 31% RRR of major bleeding compared 
with warfarin. ConClusions: There is strong evidence supporting these new tech-
nologies, especially regarding safety. Further studies are needed to support decision 
making, especially with regards to cost-effectiveness issues.
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objeCtives: Positron Emission Tomography (PET) might be useful for cancer staging 
and follow-up. The objetive was to assess the available evidence on efficacy, safety 
and coverage policies for use of PET in oncology. Methods: A bibliographic search 
was carried in PubMed, DARE, NHS EED, in health technology assessment (HTA) 
agencies and health insurers. Priority was given to systematic reviews; randomized 
clinical trials (RCTs); HTA; clinical practice guidelines (CPGs) and coverage policies 
(CPs). Results: Thirty-seven systematic reviews, 3 RCTs and 32 observational stud-
ies, 51 CPGs, 15 HTAs and 28 CPs were included. Breast Cancer (17 studies):There 
is no evidence of its use as routine practice. Some CPGs and CPs recommend it for 
suspicious images that could not be clarified through conventional studies. PET is 
not recommended for axillary staging or neodadyuvant response prediction. Lung 
Cancer (44 studies):The accuracy for lung nodule is similar to conventional methods. 
Most CPGs do not recommend the use of PET for lung cancer staging except in some 
non-small cell lung cancer with previous negative tests for metastasis. Colorectal 
Cancer (20 studies): There is no evidence of its use as routine practice. It might be 
used in patients with suspected recurrence and non-conclusive images. Genitourinary 
Tumors (70 studies): PET might be associated with changes in diagnosis or therapeutic 
only in specific cases, such as ovarian cancer with suspected recurrence and nor-
mal conventional images, in residual tumors due to seminoma and cervical cancer 
recurrence eligible for curative treatment. Primary Tumors of the Central Nervous 
System (15 studies):PET is not recommended as routine practice. CPGs, RCTs and CPs 
recognize its usefulness for differential diagnosis between relapse and radionecro-
sis. ConClusions: There is no evidence to support the use of PET in cancer patients 
as routine practice. At present, its use should be restricted to specific patients.
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objeCtives: To evaluate the efficacy, safety and cost-effectiveness data of lipid 
formulations of amphotericin B to establish which should be used for the treatment 
of systemic fungal infections in patients with HIV/AIDS in Brazil. Methods: We 
searched The Cochrane Library, Centre for Reviews and Dissemination, Tripdatabase, 
Medline and LILACS databases aiming to find systematic reviews (SRs) and eco-
nomic evaluations (EE) comparing liposomal amphotericin B (L-AmB) or ampho-
tericin B lipid complex (ABLC). Health Technology Assessments (HTA) were searched 
on agencies websites. Quality of the evidence and strength of recommendation 
were evaluated using the GRADE system. Results: We selected five SRs, in which 
one evaluated only safety data, and two economic evaluations. Four SRs were clas-
sified as poor quality and the strength of recommendation was considered weak 
in favor of L-AmB in all studies. In general there were no statistically significant 
differences in terms of survival and response to treatment (p< 0,05). However, L-AmB 
was associated with a lower risk of nephrotoxicity and increased serum creatinine. 
The two economic studies included had conflicting results. In the cost-minimization 
study there was no difference in total costs of the therapies, but the daily cost of 
acquisition and concomitant antifungal therapy and adverse events were lower 
for ABLC (0,002 and 0,027). The incremental cost-effectiveness analysis favored the 
L-AmB (€ 41734 vs. € 51724). Both studies showed important limitations and there 
were no studies considering the Brazilian context. ConClusions: Considering all 
the studies found, as well as their limitations, there is a lack of evidence to support 
the spread use of L-amB in patients with HIV/AIDS affected by fungal infections, 
unless strictly in cases where patients have abnormal renal function. Also, L-AmB 
could be used in case of intolerance to conventional amphotericin B.
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ernment in better health system performance, as well as the positive effect of 
increased public investment in health over the decade in health indicators and 
process insurance in the last 5 years. ConClusions: The results suggest a 
positive effect of central government spending on health and a negative effect 
of income inequality and margination index on maternal and infant mortali-
ties, clearly mediated by socioeconomic factors characteristic of each state. 
This methodological approach is proposed to evaluate the relationships of the 
different levels of functioning of a health system and the dynamics with the 
social determinants of these levels.
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objeCtives: As follow-up to prior work, investigate what evidence is required 
for reimbursement and prescribing of biosimilar drugs from four key therapy 
areas in six Latin American countries (Argentina, Brazil, Chile, Colombia, 
Mexico and Venezuela). Explore how these requirements may correspond to 
the regulatory pathways across the different countries. Methods: Conduct 
secondary research to determine any recent changes to biosimilar regulation in 
the six studied countries. Conduct targeted primary research with payers and 
physicians in the six counties exploring: 1) The therapy areas that payers and 
physicians consider most attractive for biosimilars; 2) The baseline evidence 
(bioequivalence, comparative trial data, extrapolation of indications, etc.) that 
stakeholders require across the key therapy areas and across countries; 3) The 
level of discount, below the branded equivalent, that payers and physicians 
would require to consider biosimilars for access or to prescribe to their patients; 
4) The expected access level and prescribing decisions for those biosimilars that 
meet these evidence and discount criteria; and 5) The degree to which payer 
and physician evidence expectations for biosimilars map to our understanding 
of the evolution of biosimilar regulatory environment. Results: Public payers 
across the region see biosimilars as an opportunity to provide broader access to 
needed medications, although some stakeholders are more receptive than oth-
ers and have lower requirements to prove comparability. Clinicians in general 
have concerns about safety and efficacy, however, their willingness to prescribe 
biosimilars correlates inversely with the degree of access and affordability of 
the branded agents. ConClusions: The regulatory and access environment for 
biosimilars in Latin America can be expected to be more favorable than in the 
US but not too dissimilar from Europe. However there are systematic differences 
across countries and therapy areas.
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objeCtivos: El Streptococcus pneumoniae causa una importante morbilidad y 
mortalidad a nivel mundial, tanto en niños como en adultos. El objetivo de este 
análisis es estimar la costo-efectividad de la vacuna conjugada 13-valente (PCV13) 
vs la vacuna neumocócica polisacárida 23-valente (PPSV23) y vs no vacunación en 
los adultos de alto riesgo (inmunocomprometidos) > 50 años en Colombia, desde 
la perspectiva del tercero pagador. MetodologíAs: Se adaptó un modelo de 
Markov con horizonte de tiempo de la expectativa de vida y tasa de descuento 3% 
anual. Los comparadores fueron PCV13, PPSV23 y no vacunación (NV), cobertura 
estimada del 70%; revacunación a los 5 años con PPSV23 para > 65 años según 
criterios del CDC. Se utilizó la población > 50 años de alto riesgo en Colombia. 
Las probabilidades de transición, incidencia de enfermedades y efectividades de 
las vacunas fueron extraídas de la literatura (para PCV13 se utilizaron datos de 
PCV7 ajustados por inmunosenescencia), los costos médicos fueron proveídos por 
una EPS de cobertura nacional; los precios de las vacunas fueron tomados de la 
OPS para 2013. Los costos se presentan en US$ 2013. Las medidas de efectividad 
fueron número de casos evitados de enfermedad neumocócica invasiva – ENI 
(meningitis y bacteremia), neumonía invasiva, muertes y años de vida ganados 
(AVG). ResultAdos: Vacunar con PCV13 vs NV y PPSV23 previene 4.389 y 4.134 
casos de ENI; 2594 casos de neumonía invasiva y 550 y 536 muertes respectiva-
mente. PCV13 genera 199 AVG más que PPSV23 y 4.712 AVG más que NV. El ahorro 
total esperado (vacunación + costos médicos) con PCV13 fue US$18,254,171 vs NV 
y US$26,204,251 vs PPSV23. ConClusiones: Vacunar adultos inmunocompro-
metidos > 50 años con PCV13 en Colombia es una alternativa costo-ahorradora en 
comparación con NV y con PPSV23 (US$12.57 y US$18.08 ahorrados por paciente 
respectivamente). Los hallazgos de este estudio soportan una toma de decisión 
a favor de PCV13.
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Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. 
Patients with AF have a 4-5 times larger risk of stroke than age-matched controls. 
Anticoagulation with warfarin is currently the standard of care but the requirement 
for routine monitoring and drug and food interactions, makes its use is suboptimal. 
New anticoagulants were developed to eliminate these barriers and the results are 
promising. However, the incorporation of these technologies within the Brazilian 
Unified Health System (SUS) demands proper consideration. objeCtives: To evalu-
